Cardiome Pharma Corp. (COM.TO) Notes Updated Guidelines From European Society of Cardiology Now Include Brinavess (Vernakalant) for Infusion
9/10/2012 8:53:48 AM
VANCOUVER, B.C., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today noted that the European Society of Cardiology (ESC) has issued updated treatment guidelines for the treatment of adult patients with recent on-set atrial fibrillation, a type of irregular heartbeat. The focused update now includes the intravenous (IV) formulation of BrinavessTM (vernakalant), among other treatments, when pharmacologic cardioversion is preferred, as first line therapy for the cardioversion of atrial fibrillation to normal sinus rhythm in patients with no or moderate structural heart disease. The new guidelines were presented as part of the annual meeting of the European Society of Cardiology Congress in Munich on August 28, 2012 and have been published in the European Heart Journal (Camm et al., (2012), European Heart Journal August 24, 2012).